Lactose India Q2 FY26: Sales ₹41.18 Cr, Capacity +50%

Key update from Q2 (Sep 2025)

Lactose (India) Ltd, a small-cap company in the Healthcare sector (Pharmaceuticals & Drugs), reported an operating and expansion update alongside its Q2 (Sep 2025) numbers. The company disclosed a manufacturing capacity enhancement for lactose products from 10,000 metric tonnes (MT) to 15,000 MT per annum. On the financial side, standalone net sales for the September 2025 quarter were reported at ₹41.18 crore, with the company also publishing unaudited revenue, profit after tax (PAT), and EPS figures for the same quarter.

Capacity expansion: 10,000 MT to 15,000 MT

The company said it has enhanced its manufacturing capacity for lactose products from 10,000 MT to 15,000 MT per annum. This change implies a 5,000 MT addition, or a 50% increase over the earlier level. Capacity additions in excipient-linked products such as lactose can matter for order fulfilment, customer onboarding, and product availability, especially when demand is stable or rising. The update is relevant because it provides investors a concrete operational datapoint beyond quarterly performance.

Standalone Q2 Sep 2025 numbers: revenue, PAT and EPS

For Q2 Sep 2025, Lactose India reported unaudited revenue of ₹41.18 crore (₹4,118.13 lakh). The company also reported PAT of ₹2.16 crore (₹215.88 lakh) and basic EPS of ₹1.71. The figures indicate profitability for the quarter, although the article data does not provide cost line items or margin details. The company’s reported standalone September 2025 net sales were also described as up 35.25% year-on-year.

Year-on-year sales: Sep 2025 vs Sep 2024

The article states that standalone September 2025 net sales were ₹41.18 crore, up 35.25% year-on-year. For comparison, the standalone September 2024 net sales were ₹30.45 crore, reported as up 24.65% year-on-year in that period. These quarterly sales datapoints show a higher base in the latest September quarter versus the previous year’s September quarter. However, the article does not provide a full quarterly series or drivers such as volume, price realisation, or product mix.

March 2025 quarter snapshot

Apart from the September quarter updates, the article includes a March 2025 standalone net sales figure. Lactose India’s standalone March 2025 net sales were ₹27.77 crore, down 5.54% year-on-year. This datapoint suggests that performance across quarters has not been uniform. With only a few quarters cited, it is difficult to infer a consistent trend from the provided information alone.

Share price move and market cap details

The stock reaction highlighted in the article shows Lactose (India) Ltd shares moved up by 5.80% from the previous close of ₹110.11 to ₹116.50. The company is described as a Small Cap with a market capitalisation of ₹145.98 crore (also referenced as about ₹146 crore in the provided text). These market metrics provide context for the stock’s liquidity and sensitivity to operational updates such as capacity increases and quarterly results.

Cash flow from investing: higher outflow cited

The article notes that the company used ₹15.57 crore for investing activities, described as a year-on-year increase of 648.85% (source cited as standalone financials). The data point indicates a larger investing cash outflow compared with the prior period referenced. The article does not break down the nature of these investing uses, but it appears alongside the company’s capacity enhancement update.

Business profile and revenue mix pointers

Lactose (India) Ltd was incorporated in 1991 and is described as manufacturing pharmaceutical products and carrying out job work. The company’s key products and revenue segments for the year ended 31-Mar-2024 are listed as Pharmaceutical Products, Conversion Charges, Scrap, and Other Operating Revenue. The article also states that LIL, associated with the Kerry Group, is involved in the production of pharmaceuticals, drugs, medicines, chemicals, and food products, and operates across manufacturing, processing, exporting, importing, and distribution.

Key facts table

Market impact: what investors are reacting to

Two datapoints stand out in the update: the sharp year-on-year rise in September-quarter net sales, and the announced capacity increase. The 5.80% move to ₹116.50, as cited, suggests the market tracked the quarterly update closely. The investing cash outflow figure also adds context, because higher investing activity often coincides with capacity additions, even though the article does not explicitly link the outflow to the lactose expansion.

Analysis: why the update matters

For a company of this market capitalisation, capacity announcements are often scrutinised because they can influence production capability and the ability to take incremental orders. The September 2025 quarter also shows a clear year-on-year uplift in sales as reported. At the same time, the presence of a weaker March 2025 quarter sales figure in the provided data highlights that quarterly performance can vary. Separately, the article states that revenues increased 2.20% YoY and EPS decreased by 23.93% YoY, indicating that earnings per share may not always track revenue direction in the periods referenced.

Company identifiers and contact details

The company’s registered office address is Survey No. 5, 6, 7A, Village Poicha (Rania), Savli, Vadodra District, Gujarat - 391780. The telephone number listed is 2667-244729 and fax is 2667-244504. The email cited is lil@lactoseindialimited.com and the website is http://www.lactoseindialimited.com. The BSE code is 524202 and the ISIN is INE058I01013.

Conclusion

Lactose (India) Ltd’s update combines an operational milestone, with lactose capacity raised from 10,000 MT to 15,000 MT per annum, and a September 2025 quarter performance snapshot showing net sales of ₹41.18 crore and PAT of ₹2.16 crore. The stock movement to ₹116.50, as cited, indicates immediate market attention to these disclosures. The next set of company filings and subsequent quarterly numbers will be important to track how the expanded capacity and investing activity reflect in reported sales and profitability.